BioSpace News Archive

IconOVir Bio, Inc. today announced that it will present preclinical data on ICVB-1042 in three poster presentations at the upcoming Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022), which is being held in Boston, MA and virtually from November 8-12, 2022.

Apnimed today announced that John Cronin, M.D., has joined the company as Senior Vice President, Clinical Development.

Clarametyx Biosciences Inc . today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application to initiate a first-in-human Phase 1 safety study followed by a Phase 1b trial of CMTX-101, a novel immune-enabling antibody therapy.

Lantern Pharma Inc. today announced that Lantern management will be presenting at two upcoming investor conferences.

Twist Bioscience Corporation today announced that Steffen Hellmold, senior vice president, business development for data storage, will present at the Joint School of Nanoscience and Nanoengineering (JSNN) NanoImpacts 2022: Semiconductor Synthetic Biology and Beyond taking place October 13-15, 2022.

Artiva Biotherapeutics, Inc. announced today that an abstract highlighting further in vivo and in vitro preclinical data for AB-101, the Company’s clinical-stage ADCC-enhancer product candidate, was accepted for presentation at the Society for Immunotherapy of Cancer (SITC).

Immunitas Therapeutics today announced they will present preclinical data on lead program IMT-009, a fully human monoclonal antibody against a novel immuno-oncology target CD161, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held both virtually and in Boston from November 8-12, 2022.

Repertoire® Immune Medicines will present data from its ongoing research to characterize the cellular response and identify novel therapeutic targets with the company’s DECODE™ platform in human papillomavirus 16 and HPV 33 positive tumors.

Xencor, Inc today announced seven poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, being held in Boston, November 10-12, 2022.

23andMe Holding Co. today announced that it will present a trials-in-progress poster presentation on 23ME-00610, an investigational antibody targeting CD200R1, at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting to be held in Boston, MA .